Bracco Suisse
Switzerland Updated 9 July 2026
Bracco Suisse is a finished-dose manufacturer based in Switzerland. It appears in 50 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA and ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 4 July 2024 as VAI.
3
registered plants
1 with an FDA FEI number
50
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 4 July 2024 VAI US FDA
- 27 November 2018 NAI US FDA
- 26 July 2016 NAI US FDA
- 8 August 2014 NAI US FDA
- 27 April 2012 OAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| PLAN-LES-QUATES, Switzerland | Not on file |
| Cadempino, Switzerland | Not on file |
| Switzerland, Switzerland | 3002740213 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| SWISSMEDIC (CH) | 50 | None |
| US FDA | None | 1 |
| ANVISA (Brazil) | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Bracco Suisse comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 4 July 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates